rcel-10q_20220331.htm
false Q1 2022 0001762303 --12-31 30 days 0.3333 P2Y P2Y P3Y 0.3333 P2Y25D P2Y3M18D http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent P2Y P11Y P14Y P20Y P20Y P13Y P20Y P19Y P19Y 0001762303 2022-01-01 2022-03-31 xbrli:shares 0001762303 2022-05-01 iso4217:USD 0001762303 2022-03-31 0001762303 2021-12-31 iso4217:USD xbrli:shares 0001762303 2021-01-01 2021-03-31 0001762303 us-gaap:CommonStockMember 2021-12-31 0001762303 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001762303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001762303 us-gaap:RetainedEarningsMember 2021-12-31 0001762303 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001762303 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001762303 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001762303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001762303 us-gaap:CommonStockMember 2022-03-31 0001762303 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001762303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001762303 us-gaap:RetainedEarningsMember 2022-03-31 0001762303 us-gaap:CommonStockMember 2020-12-31 0001762303 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001762303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001762303 us-gaap:RetainedEarningsMember 2020-12-31 0001762303 2020-12-31 0001762303 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001762303 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001762303 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001762303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001762303 us-gaap:CommonStockMember 2021-03-31 0001762303 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001762303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001762303 us-gaap:RetainedEarningsMember 2021-03-31 0001762303 2021-03-31 0001762303 rcel:NonOptionRestrictedStockUnitsMember 2022-01-01 2022-03-31 0001762303 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0001762303 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:NonUsMember 2021-01-01 2021-03-31 0001762303 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001762303 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 rcel:PerformanceObligation 0001762303 rcel:BardaMember 2022-01-01 2022-03-31 xbrli:pure 0001762303 rcel:RecellSystemMember rcel:BardaMember 2022-01-01 2022-03-31 0001762303 rcel:BardaMember rcel:EmergencyDeploymentMember 2022-01-01 2022-03-31 0001762303 rcel:BardaMember rcel:RecellSystemMember rcel:RevenueMember 2022-01-01 2022-03-31 0001762303 srt:MinimumMember 2022-01-01 2022-03-31 0001762303 srt:MaximumMember 2022-01-01 2022-03-31 0001762303 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rcel:CommercialCustomerMember rcel:EmergencyDeploymentServiceMember 2022-01-01 2022-03-31 0001762303 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rcel:CommercialCustomerMember rcel:EmergencyDeploymentServiceMember 2021-01-01 2021-03-31 0001762303 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember rcel:CommercialCustomerMember 2022-01-01 2022-03-31 0001762303 rcel:AccountsReceivableRevenueMember us-gaap:CustomerConcentrationRiskMember rcel:BardaMember rcel:EmergencyPreparednessServicesMember 2022-01-01 2022-03-31 0001762303 rcel:AccountsReceivableRevenueMember us-gaap:CustomerConcentrationRiskMember rcel:BardaMember rcel:EmergencyPreparednessServicesMember 2021-07-01 2021-12-31 0001762303 srt:MinimumMember 2022-03-31 0001762303 srt:MaximumMember 2022-03-31 rcel:Segment 0001762303 rcel:DeferredCompensationPlansMember 2022-01-01 2022-03-31 0001762303 rcel:DeferredCompensationPlansVestingTrancheOneMember rcel:DeferredCompensationPlansMember 2022-01-01 2022-03-31 0001762303 rcel:DeferredCompensationPlansVestingTrancheTwoMember rcel:DeferredCompensationPlansMember 2022-01-01 2022-03-31 0001762303 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2022-03-31 0001762303 us-gaap:USTreasurySecuritiesMember 2022-03-31 0001762303 us-gaap:CommercialPaperMember 2022-03-31 0001762303 us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001762303 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-03-31 0001762303 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001762303 us-gaap:CommercialPaperMember 2021-12-31 0001762303 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001762303 us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001762303 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001762303 rcel:ContractualMaturitiesMember 2022-03-31 0001762303 rcel:ContractualMaturitiesMember 2021-12-31 0001762303 2021-07-01 2021-12-31 0001762303 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2022-03-31 0001762303 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-03-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-03-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001762303 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001762303 2021-08-31 0001762303 rcel:PatentOneMember 2022-01-01 2022-03-31 0001762303 rcel:PatentTwoMember 2022-01-01 2022-03-31 0001762303 rcel:PatentThreeMember 2022-01-01 2022-03-31 0001762303 rcel:PatentFiveMember 2022-01-01 2022-03-31 0001762303 rcel:PatentSixMember 2022-01-01 2022-03-31 0001762303 rcel:PatentSevenMember 2022-01-01 2022-03-31 0001762303 rcel:PatentEightMember 2022-01-01 2022-03-31 0001762303 rcel:PatentTenMember 2022-01-01 2022-03-31 0001762303 rcel:PatentElevenMember 2022-01-01 2022-03-31 0001762303 rcel:PatentOneMember 2022-03-31 0001762303 rcel:PatentTwoMember 2022-03-31 0001762303 rcel:PatentThreeMember 2022-03-31 0001762303 rcel:PatentFiveMember 2022-03-31 0001762303 rcel:PatentSixMember 2022-03-31 0001762303 rcel:PatentSevenMember 2022-03-31 0001762303 rcel:PatentEightMember 2022-03-31 0001762303 rcel:PatentTenMember 2022-03-31 0001762303 rcel:PatentElevenMember 2022-03-31 0001762303 rcel:PatentOneMember 2021-12-31 0001762303 rcel:PatentTwoMember 2021-12-31 0001762303 rcel:PatentThreeMember 2021-12-31 0001762303 rcel:PatentFiveMember 2021-12-31 0001762303 rcel:PatentSixMember 2021-12-31 0001762303 rcel:PatentSevenMember 2021-12-31 0001762303 rcel:PatentEightMember 2021-12-31 0001762303 rcel:PatentTenMember 2021-12-31 0001762303 rcel:PatentElevenMember 2021-12-31 0001762303 us-gaap:TrademarksMember 2022-03-31 0001762303 us-gaap:TrademarksMember 2021-12-31 0001762303 us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0001762303 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-01 2022-03-31 0001762303 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0001762303 us-gaap:EquipmentMember 2022-01-01 2022-03-31 0001762303 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-03-31 0001762303 rcel:RecellMouldsMember 2022-01-01 2022-03-31 0001762303 us-gaap:ComputerEquipmentMember 2022-03-31 0001762303 us-gaap:ComputerEquipmentMember 2021-12-31 0001762303 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-03-31 0001762303 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0001762303 us-gaap:ConstructionInProgressMember 2021-12-31 0001762303 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001762303 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001762303 us-gaap:EquipmentMember 2022-03-31 0001762303 us-gaap:EquipmentMember 2021-12-31 0001762303 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001762303 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001762303 rcel:RecellMouldsMember 2022-03-31 0001762303 rcel:RecellMouldsMember 2021-12-31 0001762303 country:US 2022-01-01 2022-03-31 0001762303 country:US 2021-01-01 2021-03-31 0001762303 rcel:ForeignMember country:AU 2022-01-01 2022-03-31 0001762303 rcel:ForeignMember country:AU 2021-01-01 2021-03-31 0001762303 rcel:ForeignMember country:GB 2022-01-01 2022-03-31 0001762303 rcel:ForeignMember country:GB 2021-01-01 2021-03-31 0001762303 rcel:CommercialSalesMember 2022-01-01 2022-03-31 0001762303 rcel:CommercialSalesMember 2021-01-01 2021-03-31 0001762303 rcel:ProductSalesMember 2021-01-01 2021-03-31 0001762303 rcel:ServicesForEmergencyPreparednessMember 2022-01-01 2022-03-31 0001762303 rcel:ServicesForEmergencyPreparednessMember 2021-01-01 2021-03-31 0001762303 rcel:CommercialCostMember 2022-01-01 2022-03-31 0001762303 rcel:CommercialCostMember 2021-01-01 2021-03-31 0001762303 rcel:ProductCostMember 2022-01-01 2022-03-31 0001762303 rcel:ProductCostMember 2021-01-01 2021-03-31 0001762303 rcel:EmergencyPreparednessServiceCostMember 2022-01-01 2022-03-31 0001762303 rcel:EmergencyPreparednessServiceCostMember 2021-01-01 2021-03-31 0001762303 us-gaap:ThreatenedLitigationMember 2022-03-31 0001762303 us-gaap:ThreatenedLitigationMember 2021-12-31 0001762303 rcel:ShareholdersOfAvitaMedicalMember rcel:AdrsMember 2022-01-01 2022-03-31 0001762303 rcel:BardaMember 2022-01-01 2022-03-31 0001762303 rcel:BardaMember rcel:RecellSystemMember 2022-01-01 2022-03-31 0001762303 rcel:BardaMember rcel:RecellSystemMember 2022-03-31 0001762303 rcel:BardaMember rcel:RecellSystemMember 2021-12-31 0001762303 rcel:BardaMember rcel:RecellSystemMember 2021-01-01 2021-03-31 0001762303 us-gaap:OtherNoncurrentAssetsMember 2022-03-31 0001762303 us-gaap:OtherNoncurrentAssetsMember 2021-12-31 0001762303 rcel:JapanesePharmaceuticalsAndMedicalDeviceActApprovalMember rcel:RecellSystemMember 2022-03-31 0001762303 rcel:JapanesePharmaceuticalsAndMedicalDeviceActApprovalMember rcel:RecellSystemMember 2021-12-31 0001762303 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001762303 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001762303 rcel:TwoThousandAndTwentyOmnibusIncentivePlanMember us-gaap:CommonStockMember 2020-11-30 0001762303 rcel:EmployeeSharePlanAndIncentiveOptionPlanTwoThousandAndSixteenMember 2022-01-01 2022-03-31 0001762303 rcel:TwoThousandAndTwentyOmnibusIncentivePlanMember 2022-01-01 2022-03-31 0001762303 rcel:TwoThousandAndTwentyOmnibusIncentivePlanMember rcel:VestingPeriodOneMember 2022-01-01 2022-03-31 0001762303 rcel:TwoThousandAndTwentyOmnibusIncentivePlanMember rcel:VestingPeriodTwoMember 2022-01-01 2022-03-31 0001762303 rcel:TwoThousandAndTwentyOmnibusIncentivePlanMember rcel:VestingPeriodThreeMember 2022-01-01 2022-03-31 0001762303 rcel:TwoThousandAndTwentyOmnibusIncentivePlanMember rcel:VestingPeriodFourMember 2022-01-01 2022-03-31 0001762303 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001762303 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001762303 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001762303 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001762303 rcel:ServiceOnlyShareOptionsMember 2021-12-31 0001762303 us-gaap:PerformanceSharesMember 2021-12-31 0001762303 rcel:MarketAwardsMember 2021-12-31 0001762303 rcel:ServiceOnlyShareOptionsMember 2022-01-01 2022-03-31 0001762303 rcel:ServiceOnlyShareOptionsMember 2022-03-31 0001762303 us-gaap:PerformanceSharesMember 2022-03-31 0001762303 rcel:MarketAwardsMember 2022-03-31 0001762303 us-gaap:RestrictedStockUnitsRSUMember rcel:EmployeeSharePlanAndIncentiveOptionPlanTwoThousandAndSixteenMember 2022-01-01 2022-03-31 0001762303 rcel:NonOptionsServiceBasedRestrictedStockUnitsMember 2021-12-31 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember 2021-12-31 0001762303 rcel:NonOptionMarketConditionMember 2021-12-31 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-03-31 0001762303 rcel:NonOptionsServiceBasedRestrictedStockUnitsMember 2022-03-31 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember 2022-03-31 0001762303 rcel:NonOptionMarketConditionMember 2022-03-31 0001762303 rcel:LongTermIncentivePlanMember srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2019-11-01 2019-11-30 0001762303 rcel:LongTermIncentivePlanMember srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember rcel:ServiceBasedMilestoneMember 2020-06-30 0001762303 rcel:LongTermIncentivePlanMember srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember rcel:ServiceBasedMilestoneMember 2020-06-01 2020-06-30 0001762303 rcel:LongTermIncentivePlanMember srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember rcel:ServiceBasedMilestoneMember 2022-03-31 0001762303 rcel:LongTermIncentivePlanMember srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember rcel:PatientVisitForTreatmentAndRegulatoryApprovalMember 2021-06-30 0001762303 rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember 2021-12-21 2021-12-22 0001762303 us-gaap:RestrictedStockUnitsRSUMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember 2021-12-22 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-12-22 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-03-31 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-01-01 2022-03-31 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-01-01 2022-03-31 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-12-22 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-12-22 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember rcel:ShareBasedCompensationAwardTrancheFourMember 2021-12-22 0001762303 rcel:NonOptionPerformanceBasedRestrictedStockUnitsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember rcel:ShareBasedCompensationAwardTrancheFourMember 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-12-21 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-12-21 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-12-21 2021-12-22 0001762303 us-gaap:PerformanceSharesMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember rcel:ShareBasedCompensationAwardTrancheFourMember 2021-12-21 2021-12-22 0001762303 rcel:MarketAwardsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember 2021-12-22 0001762303 rcel:NonOptionMarketConditionMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember 2021-12-22 0001762303 rcel:MarketAwardsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-12-22 0001762303 rcel:NonOptionMarketConditionMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-12-22 0001762303 rcel:MarketAwardsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-12-22 0001762303 rcel:NonOptionMarketConditionMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-12-22 0001762303 rcel:MarketAwardsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-10-14 0001762303 rcel:MarketAwardsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-12-21 2021-12-22 0001762303 rcel:MarketAwardsMember rcel:TwoThousandAndTwentyOneAGMAwardsMember srt:ChiefExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-12-21 2021-12-22 0001762303 rcel:TwoThousandAndTwentyOneAGMPlanMember srt:DirectorMember rcel:ServicePeriodMilestoneMember 2021-12-21 2021-12-22 0001762303 us-gaap:RestrictedStockUnitsRSUMember rcel:TwoThousandAndTwentyOneAGMPlanMember srt:DirectorMember rcel:ServicePeriodMilestoneMember 2021-12-21 2021-12-22 0001762303 rcel:TwoThousandAndTwentyOneAGMPlanMember srt:DirectorMember rcel:VestingPercentageMilestoneMember 2021-12-21 2021-12-22 0001762303 us-gaap:RestrictedStockUnitsRSUMember rcel:TwoThousandAndTwentyOneAGMPlanMember srt:DirectorMember rcel:VestingPercentageMilestoneMember 2021-12-21 2021-12-22 0001762303 us-gaap:InternalRevenueServiceIRSMember 2021-12-31 0001762303 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001762303 us-gaap:HerMajestysRevenueAndCustomsHMRCMember 2021-12-31 0001762303 us-gaap:AustralianTaxationOfficeMember 2021-12-31 0001762303 rcel:YearTwoThousandTwentySixThroughTwoThousandAndThirtyEightMember 2021-12-31 0001762303 us-gaap:EarliestTaxYearMember 2021-07-01 2021-12-31 0001762303 us-gaap:LatestTaxYearMember 2021-07-01 2021-12-31 0001762303 us-gaap:StateAndLocalJurisdictionMember us-gaap:EarliestTaxYearMember 2021-07-01 2021-12-31 0001762303 us-gaap:StateAndLocalJurisdictionMember us-gaap:LatestTaxYearMember 2021-07-01 2021-12-31 0001762303 rcel:TaxCutAndJobsActMember 2020-07-01 2021-06-30 0001762303 rcel:TaxCutAndJobsActMember 2019-07-01 2020-06-30 0001762303 rcel:TaxCutAndJobsActMember 2018-07-01 2019-06-30 0001762303 srt:MinimumMember rcel:DeferredCompensationPlansMember 2022-01-01 2022-03-31 0001762303 srt:MaximumMember rcel:DeferredCompensationPlansMember 2022-01-01 2022-03-31 0001762303 rcel:DeferredCompensationPlansMember 2021-01-01 2021-03-31 0001762303 rcel:DeferredCompensationPlansMember 2022-03-31 0001762303 rcel:DeferredCompensationPlansMember 2021-12-31 0001762303 us-gaap:FairValueInputsLevel2Member rcel:DeferredCompensationPlansMember 2022-03-31 0001762303 us-gaap:FairValueInputsLevel2Member rcel:DeferredCompensationPlansMember 2021-12-31

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-39059

 

 

AVITA MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

85-1021707

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

 

28159 Avenue Stanford

Suite 220

Valencia, CA 91355

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code: (661) 367-9170

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol

 

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

 

RCEL

 

The NASDAQ Stock Market LLC

Securities registered pursuant to section 12(g) of the Act:

None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

 

 

 

 

 

 

 

Non-accelerated filer

 

Smaller reporting company

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has selected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

The number of shares of the registrant’s $0.0001 par value common stock outstanding as of May 1, 2022 was 24,955,581

 


 

TABLE OF CONTENTS   

 

FORWARD-LOOKING STATEMENT

3

 

 

PART I – FINANCIAL INFORMATION

4

 

 

 

Item 1.

Financial Statements

4

 

 

 

 

 

 

 

 

 

 

Consolidated Balance Sheets – March 31, 2022 (unaudited) and December 31, 2021

4

 

 

 

 

Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 (unaudited)

5

 

 

 

 

Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2022 and 2021 (unaudited)

6

 

 

 

 

Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2022 and 2021 (unaudited)

7

 

 

 

 

Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited)

8

 

 

 

 

Notes to Consolidated Financial Statements (unaudited)

9

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

30

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

34

 

 

 

Item 4.

Controls and Procedures

34

 

 

Part II – OTHER INFORMATION

35

 

 

 

Item 1.

Legal Proceedings

35

 

 

 

Item 1A.

Risk Factors

35

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

35

 

 

 

Item 3.

Defaults Upon Senior Securities

35

 

 

 

Item 4.

Mine Safety Disclosures

35

 

 

 

Item 5.

Other Information

35

 

 

 

Item 6.

Exhibits

36

 

 

Signatures

37

 

 

 


 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENT

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future revenues; solvency; future industry market conditions; future changes in our capacity and operations; future operating and overhead costs; intellectual property; regulatory and related approvals; the conduct or outcome of pre-clinical or clinical (human) studies; operational and management restructuring activities (including implementation of methodologies and changes in the board of directors); future employment and contributions of personnel; effects on the global economy of the ongoing COVID-19 pandemic, including effects on the economy of existing and future variants on the original COVID-19 strain; tax and interest rates; productivity, business process, rationalization, investment, acquisition and acquisition integrations, consulting, operational, tax, financial and capital projects and initiatives; inflationary pressures on the U.S. and global economy; changes in the legal or regulatory environment; and future working capital, costs, revenues, business opportunities, cash flows, margins, earnings and growth. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,”“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Quarterly Report on Form 10-Q titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for our management to predict all risk factors and uncertainties.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.  

 

3


 

 

PART I – Financial Information

Item 1. FINANCIAL STATEMENTS

AVITA MEDICAL, INC.

Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

 

 

 

As of

 

 

 

March 31, 2022

 

 

December 31, 2021

 

ASSETS

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

23,535

 

 

$

55,511

 

Marketable securities

 

 

59,835

 

 

 

29,649

 

Accounts receivable, net

 

 

3,481

 

 

 

3,118

 

BARDA receivables

 

 

682

 

 

 

308

 

Prepaids and other current assets

 

 

1,146

 

 

 

1,213

 

Restricted cash

 

 

201

 

 

 

201

 

Inventory

 

 

1,803

 

 

 

2,132

 

Total current assets

 

 

90,683

 

 

 

92,132

 

Marketable securities, long-term

 

 

11,684

 

 

 

19,692

 

Plant and equipment, net

 

 

1,171

 

 

 

1,262

 

Operating lease right-of-use assets

 

 

1,375

 

 

 

1,544

 

Intangible assets, net

 

 

416

 

 

 

443

 

Other long-term assets

 

 

1,162

 

 

 

942

 

Total assets

 

$

106,491

 

 

$

116,015

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

2,397

 

 

 

2,708

 

Accrued wages and fringe benefits

 

 

2,914

 

 

 

5,363

 

Other current liabilities

 

 

1,186

 

 

 

1,075

 

Total current liabilities

 

 

6,497

 

 

 

9,146

 

Contract liabilities

 

 

882

 

 

 

952

 

Operating lease liabilities, long-term

 

 

726

 

 

 

918

 

Other long-term liabilities

 

 

571

 

 

 

375

 

Total liabilities

 

 

8,676

 

 

 

11,391

 

Contingencies (Note 12)

 

 

 

 

 

 

 

 

Shareholders' Equity:

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 24,955,581

   and 24,925,743 shares issued and outstanding at March 31, 2022 and December 31, 2021,

   respectively

 

 

3

 

 

 

3

 

Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares

   issued or outstanding at March 31, 2022 and December 31, 2021

 

 

-

 

 

 

-

 

Additional paid-in capital

 

 

335,417

 

 

 

332,484

 

Accumulated other comprehensive income

 

 

7,781

 

 

 

8,060

 

Accumulated deficit

 

 

(245,386

)

 

 

(235,923

)

Total shareholders' equity

 

 

97,815

 

 

 

104,624

 

Total liabilities and shareholders' equity

 

$

106,491

 

 

$

116,015

 

 

The accompanying notes form part of the unaudited consolidated financial statements.

4


 

AVITA MEDICAL, INC.

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Revenues

 

$

7,539

 

 

$

8,765

 

Cost of sales

 

 

(1,778

)

 

 

(2,146

)

Gross profit

 

 

5,761

 

 

 

6,619

 

BARDA income

 

 

734

 

 

 

570

 

Operating expenses:

 

 

 

 

 

 

 

 

Sales and marketing expenses

 

 

(4,828

)

 

 

(3,649

)

General and administrative expenses

 

 

(7,534

)

 

 

(5,422

)

Research and development expenses

 

 

(3,620

)

 

 

(4,109

)

Total operating expenses

 

 

(15,982

)

 

 

(13,180

)

Operating loss

 

 

(9,487

)

 

 

(5,991

)

Interest expense

 

 

-

 

 

 

(3

)

Other income

 

 

28

 

 

 

7

 

Loss before income taxes

 

 

(9,459

)

 

 

(5,987

)

Income tax expense

 

 

(4

)

 

 

(10

)

Net loss

 

$

(9,463

)

 

$

(5,997

)

Net loss per common share:

 

 

 

 

 

 

 

 

Basic

 

$

(0.38

)

 

$

(0.26

)

Diluted

 

$

(0.38

)

 

$

(0.26

)

Weighted-average common shares:

 

 

 

 

 

 

 

 

Basic

 

 

24,937,999

 

 

 

22,734,335

 

Diluted

 

 

24,937,999

 

 

 

22,734,335

 

The accompanying notes form part of the unaudited consolidated financial statements.

 

5


 

 

AVITA MEDICAL, INC.

Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net loss

 

$

(9,463

)

 

$

(5,997

)

Change in foreign currency translation gain/(loss)

 

 

18

 

 

 

(18

)

Change in net unrealized loss on marketable securities, net of tax

 

 

(297

)

 

 

-

 

Comprehensive loss

 

$

(9,742

)

 

$

(6,015

)

 

The accompanying notes form part of the unaudited consolidated financial statements.  

6


 

AVITA MEDICAL, INC.

Consolidated Statements of Shareholders’ Equity

(In thousands, except shares)

(Unaudited)

 

 

 

 

Three Months Ended March 31, 2022

 

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in Capital

 

 

Accumulated Other

Comprehensive

Gain (Loss)

 

 

Accumulated

Deficit

 

 

Total

Shareholders'

Equity

 

Balance at December 31, 2021

 

 

24,925,743

 

 

$

3

 

 

$

332,484

 

 

$

8,060

 

 

$

(235,923

)

 

$

104,624

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(9,463

)

 

 

(9,463

)

Share-based compensation

 

 

-

 

 

 

-

 

 

 

2,932

 

 

 

-

 

 

 

-

 

 

 

2,932

 

Exercise of stock options

 

 

125

 

 

 

-

 

 

 

1

 

 

 

-

 

 

 

-

 

 

 

1

 

Vesting of restricted stock units

 

 

29,713

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(279

)

 

 

-

 

 

 

(279

)

Balance at March 31, 2022

 

 

24,955,581

 

 

$

3

 

 

$

335,417

 

 

$

7,781

 

 

$

(245,386

)

 

$

97,815

 

 

 

 

Three Months Ended March 31, 2021

 

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in Capital

 

 

Accumulated Other

Comprehensive

Gain (Loss)

 

 

Accumulated

Deficit

 

 

Total

Shareholders'

Equity

 

Balance at December 31, 2020

 

 

21,625,058

 

 

$

3

 

 

$

262,086

 

 

$

8,289

 

 

$

(210,781

)

 

$

59,597

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,997

)

 

 

(5,997

)

Issuance of common stock under direct placement

 

 

3,214,250

 

 

 

 

 

 

 

69,106

 

 

 

 

 

 

 

 

 

 

 

69,106

 

Issuance costs associated with direct placement

 

 

 

 

 

 

 

 

 

 

(5,109

)

 

 

 

 

 

 

 

 

 

 

(5,109

)

Share-based compensation

 

 

-

 

 

 

-

 

 

 

1,333

 

 

 

-

 

 

 

-

 

 

 

1,333

 

Exercise of stock options

 

 

3,575

 

 

 

-

 

 

 

31

 

 

 

-

 

 

 

-

 

 

 

31

 

Translation gain

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(18

)

 

 

-

 

 

 

(18

)

Balance at March 31, 2021

 

 

24,842,883

 

 

$

3

 

 

$

327,447

 

 

$

8,271

 

 

$

(216,778

)

 

$

118,943

 

 

The accompanying notes form part of the unaudited consolidated financial statements.

 

7


 

 

AVITA Medical, Inc.

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

 

Three Months Ended

 

 

 

March 31, 2022

 

 

March 31, 2021

 

Cash flow from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(9,463

)

 

$

(5,997

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

163

 

 

 

167

 

Share-based compensation

 

 

2,932

 

 

 

1,333

 

Non-cash lease expense

 

 

169

 

 

 

156

 

Remeasurement and foreign currency transaction loss

 

 

37

 

 

 

8

 

Excess and obsolete inventory related charges

 

 

97

 

 

 

243

 

BARDA deferred costs

 

 

12

 

 

 

198

 

Contract cost amortization

 

 

85

 

 

 

50

 

Provision (benefit) for doubtful accounts

 

 

1

 

 

 

(1

)

Amortization of premium of marketable securities

 

 

50

 

 

 

-

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Trade and other receivables

 

 

(362

)

 

 

(289

)

BARDA receivables

 

 

(373

)

 

 

(2,810

)

Prepaids and other current assets

 

 

67

 

 

 

(544

)

Inventory

 

 

232

 

 

 

251

 

Operating lease liability

 

 

(173

)

 

 

(161

)

Other long-term assets

 

 

(305

)

 

 

(528

)

Accounts payable and accrued expenses

 

 

(294

)

 

 

827

 

Accrued wages and fringe benefits

 

 

(2,450

)

 

 

(1,833

)

Other current liabilities

 

 

15

 

 

 

(14

)

Contract liabilities

 

 

(70

)

 

 

403

 

Other long-term liabilities

 

 

260

 

 

 

-

 

Net cash used in operations

 

 

(9,370

)

 

 

(8,541

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchase of marketable securities

 

 

(25,525

)

 

 

-

 

Maturity of marketable securities

 

 

3,000

 

 

 

-

 

Cash paid for property and equipment

 

 

(64

)

 

 

(326

)

Cash paid for patent filing fees

 

 

(12

)

 

 

(36

)

Net cash used in investing activities

 

 

(22,601

)

 

 

(362

)

Cash flow from financing activities:

 

 

 

 

 

 

 

 

Proceeds from direct placement of common stock

 

 

-

 

 

 

69,106

 

Issuance cost associated with direct placement

 

 

-

 

 

 

(5,109

)

Proceeds from exercise of stock options

 

 

1

 

 

 

31

 

Net cash provided by financing activities

 

 

1

 

 

 

64,028

 

Effect of foreign exchange rate on cash and restricted cash

 

 

(6

)

 

 

(11

)

Net decrease in cash and cash equivalents and restricted cash

 

 

(31,976

)

 

 

55,114

 

Cash and cash equivalents and restricted cash beginning of the period

 

 

55,712

 

 

 

59,966

 

Cash and cash equivalents and restricted cash end of the period

 

$

23,736

 

 

$

115,080

 

Supplemental Disclosure of Cash Flow Information

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

-

 

 

$

3

 

Plant and equipment purchases not yet paid

 

$

8

 

 

$

27

 

 

The accompanying notes form part of the unaudited consolidated financial statements.

8


 

AVITA MEDICAL, INC.

Notes to Consolidated Financial Statements

(Unaudited)

1. The Company

Nature of the Business

The AVITA group of companies (comprising AVITA Medical, Inc. (“AVITA” or the “Company”) and its subsidiaries, including AVITA Medical Pty Limited, previously known as AVITA Medical Limited, (“AVITA Medical”)) (collectively, “AVITA Group” or “we”, “us”, or “our”) is a commercial-stage regenerative medicine company focused on the treatment of burns, trauma and other acute injuries, together with skin defects like vitiligo. The Company’s lead product is the RECELL® System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin™ Cells using a small sample of the patient’s own skin. In September 2018, the United States Food & Drug Administration (“FDA”) granted premarket approval (“PMA”) to the RECELL System for use in the treatment of acute thermal burns in patients eighteen years and older. Following receipt of our original PMA, we commenced commercializing the RECELL System in January 2019 in the United States. In June 2021 the FDA approved an expanded indication to include treatment of pediatric acute full-thickness thermal burns. In February 2022, the FDA approved a PMA supplement for the RECELL® Autologous Cell Harvesting Device with enhanced ease-of-use, aimed at providing clinicians a more efficient user experience and simplified workflow. In addition, the FDA has granted the Company Investigational Device Exemptions (“IDEs”) which have enabled the Company to initiate pivotal clinical trials to further expand the approval of the RECELL System for soft tissue reconstruction and vitiligo. Enrollment of those clinical trials is complete and, if successful, those studies would enable the Company to seek FDA approval to market the RECELL System in the United States in those indications.

 

In February 2019 we entered into a collaboration with COSMOTEC, an M3 Group company, to market and distribute the RECELL System in Japan. We worked with COSMOTEC to advance our application for approval of the RECELL System in Japan pursuant to Japan’s Pharmaceuticals and Medical Devices Act (“PMDA”).  In February 2022, COSMOTEC’s application for regulatory approval was approved by the PMDA initially with labelling for burns only.  COSMOTEC plans to commercially launch RECELL in Japan following Japan’s Ministry of Health, Labour, and Welfare approval of reimbursement pricing.   Once soft tissue and vitiligo data are available from the Company’s related U.S. clinical trials, COSMOTEC plans to submit a further application for soft tissue and vitiligo indications.

In March 2020, the World Health Organization declared the outbreak of a novel strain of the coronavirus (“COVID-19”) a pandemic. We continue to closely monitor the recent developments surrounding the continued spread and potential resurgence of COVID-19 due to existing and future variants. As a result of the pandemic, our customers (primarily hospitals) are experiencing disruptions with respect to a shortage in operating room personnel.  Although the number of U.S. hospitalizations due to COVID-19 has decreased in the last several months and many government imposed restrictions have been lifted, we continue to be unable to predict the full impact that the ongoing COVID-19 pandemic will have on our future results of operations, liquidity and financial condition due to numerous uncertainties, including the duration of the pandemic, the actions that may be taken in the future by government authorities across the United States in response to new variants. The Company has assessed the potential impact of COVID-19 on certain accounting matters including, but not limited to, the allowance for doubtful accounts, inventory reserves and return reserves, and impairment considerations for long-lived assets, marketable securities and intangibles, as of March 31, 2022 and through the date of this report.  With respect to future operating results, it is not possible at this time to predict, with any degree of precision, the effects of COVID-19. Consequently, actual results for accounting estimates and assumptions, particularly those relating to the recoverability of certain intangible assets and estimates of expected credit losses on accounts receivable could differ from these estimates. However, we do not currently believe that COVID-19 will result in any significant changes in costs going forward. We will continue to monitor the performance of our business and reassess the impacts of COVID-19 and its variants.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Transition Report on Form 10-KT for the transition period ended December 31, 2021 filed with the SEC on February 28, 2022 (United States) and the ASX on March 01, 2022 (Australia) (the “Transition Report”).

9


 

There have been no changes to the Company’s significant accounting policies as described in the Transition Report on Form 10-KT that have had a material impact on the Company’s consolidated financial statements. See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the Transition Report.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.

 

Use of Estimates

 

The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, accounting for marketable securities, income taxes, stock-based compensation, and the stand-alone selling price for the BARDA contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.

Foreign Currency Translation and Foreign Currency Transactions

The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive gain (loss) in shareholders’ equity. Gains and losses resulting from foreign currency transactions are included in general and administrative expenses and were a loss of $22,000 and gain of $8,000 for the three months ended March 31, 2022 and 2021, respectively.

The Company’s non-operating subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements and foreign currency transactions are included in general and administrative expenses.  During the three months ended March 31, 2022 and 2021, the Company recorded losses of $15,000 and $16,000, respectively.

Comprehensive Income (Loss)

The components of comprehensive income (loss) consist of net income (loss), foreign currency translation adjustments from its subsidiaries not using the U.S. dollar as their functional currency and unrealized gains and losses in investments available for sale. The Company did not have reclassifications from other comprehensive income (loss) to net loss during the quarter ended March 31, 2022.

Revenue Recognition

 

The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services.

 

To determine revenue recognition for arrangements that are within the scope of Accounting Standard Codification (“ASC”) Topic 606, Revenue Recognition, the Company performs the following five steps:

 

1.

Identify the contract with a customer

2.

Identify the performance obligations

3.

Determine the transaction price

4.

Allocate the transaction price to the performance obligations

5.

Recognize revenue when/as performance obligation(s) are satisfied

 

In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. Once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised with each contract, determines whether those are performance obligations and the related transaction price. The Company then recognizes the sale of goods based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

 

10


 

 

The Company’s revenue consists primarily of the sale of the RECELL System to hospitals or other treatment centers and to BARDA (collectively, “customers”), predominately in the United States. The Company evaluated the BARDA contract and concluded that a portion of the arrangement, such as the procurement of the RECELL system and the emergency preparedness, represents a transaction with a customer and as such are in the scope of ASC 606.  Amounts received from BARDA for the research and development of the Company’s product are classified as BARDA income in the consolidated statement of operations and are accounted for under IAS 20.  For further details refer to BARDA Income and Receivables below.

 

Revenues for commercial customers (hospitals and treatment centers) are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. For the Company’s contracts that have an original duration of one year or less, the Company elected the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred.

 

For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units, (ii) emergency preparedness services. Through this contract the Company promises to procure the product through a vendor management inventory arrangement and to stand ready to provide emergency deployment services related to the product. Emergency preparedness services include procuring necessary storage containers, housing, and maintaining the containers (and product), and providing shipping and handling services in the event of an emergency situation. This stand ready obligation is a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, overtime as services are consumed.  

 

The total transaction price for the portion of the BARDA contract that is within the scope of ASC 606, was determined to be $9.2 million.  The transaction price was allocated on a stand-alone selling price basis as follows: $7.6 million to the procurement of the RECELL product, which is classified as revenues when recognized in the consolidated statement of operations and $1.6 million to the emergency deployment services which is classified as revenues when recognized in the consolidated statement of operations.  The $1.6 million for emergency deployment includes variable consideration which is deemed immaterial to the contract as a whole.  The Company estimated the stand-alone selling price of the procurement of the RECELL product based on historical pricing of the Company’s product at the initial execution of the contract. The Company estimated the stand-alone selling price of the emergency deployment services performed based on the Company’s projected cost of providing the services plus an applicable profit margin as denoted in the contract.

 

The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. The product procurement performance obligation is satisfied at a point in time, upon transfer of control of the product. As such, the related revenue for these performance obligations is recognized at a point in time as revenue within the Company’s consolidated statement of operations. In addition to guidance under ASC 606, the Company recognizes revenue from the sales of RECELL product to BARDA for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation, Commission Guidance regarding Accounting for Sale of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS). Under this guidance, revenue is recognized when product is placed in the BARDA vendor-managed inventory as control of the product has been transferred to the customer at the time of delivery to the VMI.  RECELL units that have been delivered to BARDA have a product replacement obligation at no cost to BARDA due to product’s limited shelf-life. The estimated cost of the expired inventory over the term of the contract is recognized on a per unit basis at the time of delivery. The liability is released upon replacement of the product along with a corresponding reduction to inventory. The emergency preparedness services performance obligation is satisfied over time.  Revenue for the emergency deployment will be recognized on a straight-line basis during the term of the contract as services are consumed over time. Services recognized are included in sales within the consolidated statement of operations. Contract costs to fulfil the performance obligations are incremental and expected to be recovered are capitalized and amortized on a straight-line basis over the term of the contract. Contract costs are included in other long-term assets.

Contract Liabilities

The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30-90 days, and do not include a financing component.  Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer.

11


 

 

Cost of Sales

 

Cost of sales related to products includes costs to manufacture or purchase, package, and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized.

 

Income Taxes

 

Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income or loss in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.

 

The Company reviews its uncertain tax positions regularly. An uncertain tax position represents the Company’s expected treatment of a tax position taken in a filed return or planned to be taken in a future tax return or claim that has not been reflected in measuring income tax expense for financial reporting purposes. The Company recognizes the tax benefit from an uncertain tax position when it is more-likely-than-not that the position will be sustained upon examination on the basis of the technical merits or the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired.

Cash and Cash Equivalents

Consists of cash held at deposit institutions and cash equivalents.  Cash equivalents consist of short-term highly liquid investments with original maturities of three months or less from the date of purchase and consist primarily of money market funds. The Company holds cash at deposit institutions in the amount of $6.9 million and $4.4 million of which $760,000 and $203,000 is denominated in foreign currencies in foreign institutions as of March 31, 2022 and December 31, 2021, respectively. As of March 31, 2022 and December 31, 2021, the Company held cash equivalents in the amount of $16.6 million and $51.1 million, respectively.

Restricted Cash

Pursuant to a contractual agreement to maintain the business credit card, the Company must maintain restricted cash deposits which amounted to approximately $201,000 and $201,000 as of March 31, 2022 and December 31, 2021, respectively.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, BARDA receivables and other receivables. As of March 31, 2022 and December 31, 2021, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held.

As of March 31, 2022 no single commercial customer accounted for more than 10% of total revenues or net accounts receivable.  BARDA revenue for emergency deployment accounted for approximately 1% and 47% of total revenues for the three months ended March 31, 2022 and 2021, respectively.  BARDA receivables for emergency preparedness services accounted for 1% and 3% of total BARDA receivables as of March 31, 2022 and December 31, 2021, respectively. See table below for breakdown of BARDA receivables (in thousands).

 

 

 

As of

March 31,

2022

 

 

As of

December 31,

2021

 

BARDA procurement and emergency preparedness services

 

$

8

 

 

$

9

 

BARDA expense reimbursements

 

 

674

 

 

 

299

 

Total BARDA receivables

 

$

682

 

 

$

308

 

12


 

 

Marketable Securities

We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date. Classification is determined at the time of purchase and re-evaluated each balance sheet date. Short-term marketable securities represent investment of cash available for current operations.   We account for our marketable securities as available-for-sale securities.  

All marketable securities, which consist of corporate debt securities, U.S government agency obligations, U.S treasury and commercial paper are denominated in the U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders equity until realized. Realized gains and losses on marketable securities are included in other income in the accompanying Consolidated Statements of Operations. The cost of any marketable securities sold is based on the specific identification method. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in other income. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the maximum final maturity from the date of purchase is thirty-seven months.

If necessary, the Company will recognize an allowance for credit losses on available-for-sale debt securities on an individual basis, and will no longer consider other than-temporary impairment or immediately reduce the cost basis of the investment provided that it is more likely than not that the security will be held to recovery or maturity. Further, the Company will recognize any improvements in estimated credit losses on available-for-sale debt securities immediately in earnings and reduce the existing allowance for credit losses. The Company will disaggregate its available-for-sale debt securities into the following categories: commercial paper, corporate debt, government and agency securities and money market funds. The Company’s corporate bonds are comprised of predominantly high-grade corporate bonds while its government and agency securities are U.S. treasury bonds, and U.S. agency bonds. The Company has analyzed both corporate bonds and government and agency securities and identified that both types of securities have similar risk characteristics in that they are traded infrequently and have contractual interest rates and maturity dates.

To evaluate for impairment, management reviews credit rating changes, securities trends, interest rate movements and unrealized loss at the security level of the Company’s available for sale debt securities. If any of these give rise to a potential credit concern, the Company performs a discounted cash flow analysis to determine the credit portion of the impairment. The discounted cash flow analysis will be performed either internally or through the assistance of a qualified third party. Once the credit component of the impairment is determined, the Company will record the impaired amount as an allowance to the available-for-sale debt securities balance and as a charge to other income in the accompanying Consolidated Statements of Operations, not to exceed the amount of the unrealized loss. The Company assesses expected credit losses at the end of each reporting period and adjusts the allowance through other income.

BARDA Income and Receivables

The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“BARDA”) contract in September 2015. The contract with BARDA expires December 31, 2023. Under this arrangement BARDA supported the Company’s research and development for the Company’s product, including the U.S. clinical regulatory program targeted towards PMA, our compassionate use program, clinical and health economics research. Currently, the BARDA contract is supporting the Company’s clinical trial in soft-tissue reconstruction.

Consideration received under the BARDA arrangement is earned and recognized under a cost-plus-fixed-fee arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs and a fixed-fee earned. Billings under the contracts are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, general and administrative expenses and a fixed fee.

The Company has concluded that grants under the BARDA arrangement are not within the scope of ASC 606, as it does not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition also does not apply, as the Company is a business entity and the payments are with governmental agencies or units. With respect to the BARDA arrangement, we considered the guidance in IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy. BARDA income and related receivables are recognized when there is reasonable assurance that the amount will be received, and all attaching conditions have been complied with. When the payment relates to an expense item, the amount received is recognized as income over the period when the expense was incurred.

13


 

Leases

The Company has operating leases for corporate office space, manufacturing and warehouse facility.  The Company’s operating leases have remaining lease terms of one year to two years, some of which include options to renew the lease.  At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet.

Right of use (“ROU”) assets represent the Company’s right to control an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an explicit rate, the Company used its incremental borrowing rate (“IBR”) based on the information available at commencement date in determining the discount rate used to present value lease payments. In determining the IBR, the Company considered its credit rating and current market interest rates. The IBR used approximates the interest that the Company would be required to pay for a collateralized loan over a similar term. The Company’s leases typically do not include any residual value guarantees or asset retirement obligations.

The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. Lease expense is recognized on a straight-line basis over the lease term and is primarily included in general and administrative expenses in the accompanying consolidated statements of operations.

The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all underlying asset classes. Some leases require variable payments for common area maintenance, property taxes, parking, insurance and other variable costs. The variable portion of lease payments is not included in operating lease assets or liabilities. Variable lease costs are expensed when incurred.

Share-based compensation

The Company records compensation expense for stock options based on the fair market value of the awards on the date of grant. The fair value of share-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is measured based on the number of shares ultimately expected to vest, estimated at each reporting date based on management’s expectations regarding the relevant performance criteria, if any. The Black-Scholes option pricing model and Monte Carlo Simulation were used to estimate the fair value of the time-based and performance-based options, respectively.  Under ASU 2016-09, Compensation – Stock Compensation (“ASC 718”) Improvements to Employee Share-Based Payment Accounting, the Company elected to account for forfeitures as they occur.

The following assumptions were used in the valuation of stock options.

 

Expected volatility – determined using the average of the historical volatility using daily intervals over the expected term and the derived volatility using the longest term available of 12 months.

 

Expected dividends - based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future

 

Expected term – the expected term of the Company’s stock options for tenure only vesting has been determined utilizing the “simplified” method as described in the SEC’s Staff Accounting Bulletin No. 107 relating to share-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history of awards granted, the first plan was established in 2016 and was primarily used for Executives awards.  Further, the Company does not have sufficient history of exercises in the U.S. market given the recent redomiciliation to the United States during 2020. The expected term of options with a performance condition was set to the contractual term of 10 years.  

 

Risk-free interest rate – the risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award.

14


 

Segment Reporting

 

Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as one segment.  

 

Deferred Compensation Plan and Investments in Corporate-Owned Life Insurance

 

The Company’s Deferred Compensation Plan (the "DCP"), which became effective on October 2021, allows highly compensated key employees to elect to defer a portion of their salary, bonus, commissions and RSU awards to later years. Management determined that the DCP shall be accounted for similar to a defined benefit plan under ASC 715, Compensation – Retirement Benefits, and should follow accounting treatment similar to a cash balance plan. Management determined that the employee portion and employer portion of the deferred compensation should be recognized as compensation expense with a corresponding credit to deferred compensation liability.  The matching contribution will be accrued over the vesting period of two-years with 25% vesting in the first year and 75% vesting in the second year.  Employees aged 55 or older immediately vest in employer matching contributions. The change in the liability between each reporting period is accounted for as compensation expense with a corresponding adjustment to deferred compensation liability.  Upon distribution, the Company will record the distribution as a decrease to compensation liability with corresponding credit to cash.  The Company funds the DCP through a Corporate-Owned Life Insurance (COLI).  Per the ASC 325-30-25-1A, Investments Other, COLI is recorded as an asset in other long-term assets as it does not meet the definition of a plan asset under ASC 715.  The Company invests in COLI policies relating to its deferred compensation plan.  Investments in COLI policies are recorded at their cash surrender values as of each balance sheet date. Changes in the cash surrender value during the period are recorded as a gain or loss in the statement of operations in other income.

3. Accounting Standards Update

Recently Adopted Accounting Pronouncements

In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance.” ASC 832 requires business entities to provide certain disclosures when they (1) have received government assistance and (2) use a grant or contribution accounting model by analogy to other accounting guidance. The guidance will require business entities to disclose the nature of the transactions, accounting policies used to account for the transactions, and state which line items on the balance sheet and income statement are affected by these transactions and the amount applicable to each financial statement line. Business entities will also have to disclose significant terms and conditions of transactions with a government such as the duration of the agreement, any commitments made by either side, provisions, and contingencies. The guidance in ASU 2021-10 is effective for all entities for fiscal years beginning after December 15, 2021. Entities may apply the provision either (1) prospectively to all transactions within the scope of ASC 832 that are reflected in the financial statements as of the adoption date and all new transactions entered into after the date of adoption or (2) retrospectively. The Company adopted this standard as of January 1, 2022. The adoption did not have a material impact on the Consolidated Financial Statements or disclosures.  

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, or ASU 2019-12, which includes amendments to simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC 740, Income Taxes, or ASC 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. The new guidance is effective for the Company for annual periods beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The Company adopted this standard as of January 1, 2022. The adoption did not have a material impact on the Consolidated Financial Statements.

 

15


 

 

Recent Accounting Pronouncements Not Yet Adopted

All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

 

4. Marketable Securities

The following table summarizes the amortized cost and estimates fair values of debt securities available for sale:

 

 

 

March 31, 2022

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Holding

Gains

 

 

Gross

Unrealized

Holding

Losses

 

 

Carrying

Value

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash Equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

16,617

 

 

$

-

 

 

$

-

 

 

$

16,617

 

Current marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S Treasury securities

 

$

27,246

 

 

$

1

 

 

$

(114

)

 

$

27,133

 

Commercial paper

 

 

21,331

 

 

 

-